Clinical Trials Logo

Stage IIC Rectal Cancer clinical trials

View clinical trials related to Stage IIC Rectal Cancer.

Filter by:

NCT ID: NCT01726296 Completed - Clinical trials for Stage IIIB Non-small Cell Lung Cancer

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Start date: January 2013
Phase: N/A
Study type: Interventional

This clinical trial studies adherence to survivorship care guidelines in health care providers for non-small cell lung cancer or colorectal cancer survivor care. The completion of an educational intervention by health care providers may increase compliance and adherence to National Comprehensive Cancer Network guidelines for survivorship care.

NCT ID: NCT01197664 Terminated - Clinical trials for Stage IIIB Rectal Cancer

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

Start date: August 2010
Phase: Phase 1
Study type: Interventional

This randomized pilot clinical trial studies the side effects of giving paricalcitol together with fluorouracil and radiation therapy in treating patients with rectal cancer that can be removed in surgery. Paricalcitol may help rectal cancer cells become more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. It not yet known if chemotherapy and radiation therapy are more effective with or without paricalcitol in treating rectal cancer

NCT ID: NCT00754494 Completed - Clinical trials for Recurrent Rectal Cancer

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Start date: July 2008
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well erlotinib hydrochloride works in treating patients with stage I-III colorectal cancer or adenoma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Erlotinib hydrochloride may also stop tumors from growing or coming back

NCT ID: NCT00003799 Completed - Clinical trials for Adenocarcinoma of the Rectum

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

Start date: May 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of radiation therapy plus chemotherapy followed by surgery and additional chemotherapy in treating patients who have advanced nonmetastatic primary cancer of the rectum. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may be an effective treatment for rectal cancer